Acumen Pharmaceuticals, Inc. ABOS 深 滬
等待開盤 09-10 09:30:00 美东时间
1.44
+0.030
+2.13%
華盛通- 最 高1.44
- 今 開1.41
- 成交量 9.44万股
- 最 低 1.38
- 昨 收 1.41
- 總市值 8722.57万
- 52周最高 3.36
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 0.8551
- 委 比 15.85%
- 總股本 6057.34万
- 歷史最高 26.98
- 量 比 0.80
- 振 幅 4.26%
- 歷史最低 0.8551
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences: the Citi’s 2025 Biopharma Back to School Conference on September 2, 2025, and the Cantor Global Healthcare Conference 2025 on September 5, 2025. The company, focused on developing therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease, is advancing its product candidate sabirnetug in a Phase 2 trial. It is also exploring sub...
08-26 20:00
美股大行评级 | 潜在涨幅17.9%！Stifel维持英伟达"买入"评级，目标价升至212美元；美银首予Figma"中性"评级，目标价85美元
今日重点评级关注：Stifel：维持英伟达"买入"评级，目标价从202美元升至212美元；蒙特利尔银行：维持Sabra Health Care REIT"与大市齐平"评级，目标价从19美元升至22美元
08-26 10:29
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $9
B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $10 to $9.
08-26 00:53
Acumen Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Acumen Pharmaceuticals shares are trading lower after the company reported wors...
08-12 22:34
Acumen Pharmaceuticals Q2 EPS $(0.68) Misses $(0.52) Estimate
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.52) by 31.53 percent. This is a 100 percent decrease over losses of $(0.34) per share
08-12 19:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Acumen Pharmaceuticals's Earnings: A Preview
Acumen Pharmaceuticals (NASDAQ:ABOS) will release its quarterly earnings report...
08-12 03:03
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease, announced it will report second quarter 2025 financial results on August 12, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. Registration for the call is required in advance. The webcast will al...
08-05 20:00
快讯 | Acumen制药公司与Jcr制药公司签署战略合作、选项和许可协议，共同开发增强型脑部输送™疗法治疗阿尔茨海默病
Acumen Pharmaceuticals and Jcr Pharmaceuticals Enter Strategic Collaboration, O...
07-15 19:00
快讯 | Acumen制药公司 - 预计2026年初发布阿尔茨海默病治疗的临床前数据
Acumen Pharmaceuticals Inc - Preclinical Data Expected in Early 2026 for Alzhei...
07-15 19:00
